BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer.

[MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. RNA, Messenger / analysis. Uterine Cervical Neoplasms / diagnosis

[MeSH-minor] Female. Humans. Mass Screening / methods. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / virology

MedlinePlus Health Information. consumer health - Cervical Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]

[Cites] Int J Cancer. 2007 Jan 15;120(2):351-6 [17066437.001]

[Cites] Cancer. 2006 Dec 25;108(6):494-500 [17063495.001]

[Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]

[Cites] Cancer. 2007 Feb 25;111(1):1-14 [17219448.001]

[Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]

[Cites] J Low Genit Tract Dis. 2007 Apr;11(2):98-104 [17415114.001]

[Cites] Cancer. 2007 Apr 25;111(2):83-92 [17334990.001]

[Cites] Br J Cancer. 2007 May 7;96(9):1419-24 [17342094.001]

[Cites] Clin Cancer Res. 2007 May 1;13(9):2599-605 [17473189.001]

[Cites] Int J Gynecol Pathol. 2007 Jul;26(3):223-8 [17581402.001]

[Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]

[Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]

[Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]

[Cites] Mol Diagn. 2001 Jun;6(2):125-30 [11468697.001]

[Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]

[Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]

[Cites] Acta Cytol. 2002 Jan-Feb;46(1):25-9 [11843554.001]

[Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]

[Cites] J Mol Diagn. 2002 May;4(2):97-102 [11986400.001]

[Cites] Cancer. 2002 Apr 15;94(8):2199-210 [12001118.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1948-52 [16103442.001]

[Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]

[Cites] Gynecol Oncol. 2005 Dec;99(3):578-84 [16139346.001]

[Cites] Cancer. 2005 Dec 25;105(6):461-7 [16116604.001]

[Cites] Int J Cancer. 2006 Mar 1;118(5):1254-60 [16161049.001]

[Cites] Dis Markers. 2007;23(4):273-81 [17627062.001]

[Cites] Dis Markers. 2007;23(4):315-30 [17627065.001]

[Cites] Int J Cancer. 2004 Mar 1;108(6):871-6 [14712490.001]

[Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]

[Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]

[Cites] Int J Cancer. 2007 Dec 15;121(12):2787-93 [17722112.001]

[Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]

[Cites] J Clin Pathol. 2008 Jan;61(1):132-7 [17468293.001]

[Cites] J Natl Compr Canc Netw. 2008 Jan;6(1):83-95 [18267061.001]

[Cites] Am J Surg Pathol. 2008 Apr;32(4):502-12 [18223479.001]

[Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]

[Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]

[Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]

[Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]

[Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]

[Cites] Cancer. 2003 Apr 25;99(2):89-96 [12704688.001]

[Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]

[Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]

[Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]

[Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6 [15006929.001]

[Cites] J Med Virol. 2004 May;73(1):65-70 [15042650.001]

[Cites] Acta Cytol. 2004 Mar-Apr;48(2):173-80 [15098536.001]

[Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]

[Cites] Cancer. 2004 Jun 25;102(3):142-9 [15211472.001]

[Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]

[Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]

[Cites] Diagn Cytopathol. 2004 Oct;31(4):235-42 [15452898.001]

[Cites] Hum Pathol. 1992 Feb;23(2):117-28 [1310950.001]

[Cites] J Virol Methods. 1991 Dec;35(3):305-13 [1667790.001]

[Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]

[Cites] Gynecol Oncol. 1995 Feb;56(2):239-44 [7896192.001]

[Cites] J Virol Methods. 1995 Jul;54(1):75-81 [7559859.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]

[Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]

[Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]

[Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]

[Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]

[Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]

[Cites] J Virol Methods. 2005 Mar;124(1-2):211-5 [15664071.001]

[Cites] Mod Pathol. 2005 Feb;18(2):267-73 [15492761.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 [15734959.001]

[Cites] Int J Cancer. 2005 May 10;114(6):973-6 [15645423.001]

[Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]

[Cites] Zentralbl Gynakol. 2005 Jun;127(3):140-5 [15915391.001]

[Cites] Gynecol Oncol. 2005 Jun;97(3):908-15 [15943992.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]

[Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]

[Cites] Int J Cancer. 2006 Feb 15;118(4):791-6 [16287075.001]

[Cites] Mod Pathol. 2006 Mar;19(3):384-91 [16415792.001]

[Cites] Clin Sci (Lond). 2006 May;110(5):525-41 [16597322.001]

[Cites] J Clin Microbiol. 2006 Apr;44(4):1310-7 [16597856.001]

[Cites] Cancer. 2006 Apr 25;108(2):119-23 [16411180.001]

[Cites] Int J Cancer. 2006 Sep 1;119(5):1102-7 [16570279.001]

[Cites] Br J Dermatol. 2006 Jul;155(1):129-36 [16792764.001]

[Cites] J Clin Pathol. 2006 Aug;59(8):827-30 [16467166.001]

[Cites] J Virol Methods. 2006 Oct;137(1):58-62 [16828171.001]

[Cites] Gynecol Oncol. 2006 Oct;103(1):62-6 [16494930.001]

[Cites] Gynecol Oncol. 2006 Oct;103(1):18-20 [16919709.001]

[Cites] J Clin Pathol. 2006 Oct;59(10):1017-28 [16679355.001]

(PMID = 18842994.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Grant] United States / Intramural NIH HHS / / ZIA CP010124-14

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RNA, Messenger

[Number-of-references] 89

[Other-IDs] NLM/ NIHMS212843; NLM/ PMC2900792

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Benign prostate hyperplasia (BPH-1), LnCap and PC3 cells were treated with varying concentrations of soy extract, genistein or daidzein and analyzed for cell cycle alterations and induction of apoptosis.

No significant changes in cell cycle arrest or apoptosis were observed in non-cancerous BPH-1 cells treated with soy extract, suggesting that the effects of soy extract may be tumor cell specific.

[MeSH-minor] Anticarcinogenic Agents / pharmacology. Caspases / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Dietary Supplements. Enzyme Activation / drug effects. Humans. Male. NF-kappa B / metabolism. Phytoestrogens / pharmacology. Plant Extracts / pharmacology. bcl-2-Associated X Protein / metabolism

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Invest. 2003;21(5):744-57 [14628433.001]

[Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]

[Cites] Cancer Res. 1993 Mar 15;53(6):1328-31 [8443813.001]

[Cites] Lancet. 1993 Nov 13;342(8881):1209-10 [7901532.001]

[Cites] Mutagenesis. 1994 Mar;9(2):101-6 [8201941.001]

[Cites] Carcinogenesis. 1996 Jul;17(7):1451-7 [8706248.001]

[Cites] Proc Soc Exp Biol Med. 1998 Mar;217(3):310-6 [9492340.001]

[Cites] J Cell Biochem. 1998 Apr 1;69(1):44-54 [9513045.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1055-65 [9829717.001]

[Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]

[Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]

[Cites] Nutr Cancer. 1999;33(2):125-31 [10368806.001]

[Cites] J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S [15570058.001]

[Cites] J Nutr. 2005 Jun;135(6):1400-6 [15930444.001]

[Cites] Int J Cancer. 2005 Nov 20;117(4):667-9 [15945102.001]

[Cites] J Agric Food Chem. 2005 Nov 2;53(22):8542-50 [16248551.001]

[Cites] BJU Int. 2005 Dec;96 Suppl 2:30-4 [16359436.001]

[Cites] J Nutr. 2006 Jan;136(1):75-82 [16365062.001]

[Cites] Prostate. 2006 Apr 1;66(5):557-66 [16372328.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45 [17337648.001]

[Cites] J Nutr. 2007 Apr;137(4):964-72 [17374662.001]

[Cites] Biochim Biophys Acta. 2007 Jun;1773(6):903-11 [17490757.001]

[Cites] Nutr Cancer. 2007;57(2):184-93 [17571952.001]

[Cites] Prostate Cancer Prostatic Dis. 2008;11(1):6-12 [17923857.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Oncol Rep. 2008 Apr;19(4):1061-6 [18357397.001]

[Cites] Oncogene. 2008 Oct 20;27(48):6252-75 [18931692.001]

[Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]

[Cites] Nutr Cancer. 1999;35(2):167-74 [10693171.001]

[Cites] Jpn J Cancer Res. 2000 Feb;91(2):164-73 [10761703.001]

[Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1705S-7S; discussion 1708S-9S [10837323.001]

[Cites] Prostate. 2001 May 15;47(3):183-8 [11351347.001]

[Cites] Oncogene. 2001 Jul 12;20(31):4188-97 [11464285.001]

[Cites] J Nutr. 2001 Nov;131(11 Suppl):3095S-108S [11694655.001]

[Cites] Prostate. 2002 May 1;51(2):133-40 [11948968.001]

[Cites] Clin Cancer Res. 2002 Jul;8(7):2369-77 [12114442.001]

[Cites] J Nutr. 2002 Oct;132(10):3168-71 [12368413.001]

[Cites] Oncogene. 2003 Jul 24;22(30):4702-9 [12879015.001]

[Cites] Toxicol Lett. 2004 Apr 15;150(1):43-56 [15068824.001]

[Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72 [15134504.001]

[Cites] Carcinogenesis. 2004 Sep;25(9):1649-57 [15131010.001]

[Cites] Urology. 2004 Sep;64(3):510-5 [15351581.001]

[Cites] Annu Rev Plant Biol. 2004;55:225-61 [15377220.001]

[Cites] Int J Oncol. 2004 Nov;25(5):1389-95 [15492830.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Br J Nutr. 2004 Apr;91(4):513-31 [15035679.001]

(PMID = 20404023.001).

[ISSN] 1535-3699

[Journal-full-title] Experimental biology and medicine (Maywood, N.J.)

[ISO-abbreviation] Exp. Biol. Med. (Maywood)

[Language] eng

[Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / CA107693; United States / NCI NIH HHS / CA / R01 CA107693; United States / NIA NIH HHS / AG / P01 AG024387; United States / NIA NIH HHS / AG / P01-AG024387; United States / NCCIH NIH HHS / AT / P50 AT006268; United States / NIEHS NIH HHS / ES / P30 ES000210

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BAX protein, human; 0 / Isoflavones; 0 / NF-kappa B; 0 / Phytoestrogens; 0 / Plant Extracts; 0 / bcl-2-Associated X Protein; 1POG3SCN5T / genistin; 6287WC5J2L / daidzein; EC 3.4.22.- / Caspases

[Other-IDs] NLM/ NIHMS617415; NLM/ PMC4125131

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignancies of the anal margin and perianal skin.

Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.

Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.

Proper diagnosis requires a high index of suspicion on the part of the surgeon.

Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.

Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]

[Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]

[Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]

[Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]

[Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]

[Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]

[Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]

(PMID = 20436838.001).

[ISSN] 1530-9681

[Journal-full-title] Clinics in colon and rectal surgery

[ISO-abbreviation] Clin Colon Rectal Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2780245

[Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: 102 patients with TCC, 60 with benign urinary diseases, and 60 healthy controls were included in this study.

RESULTS: The HE4 level was significantly increased in patients with TCC compared to patients with benign urinary diseases patients (P<0.01) and healthy controls (P<0.01), and the level of HE4 in patients with superficial TCC (Tis Ta T1) was significantly higher than that of the benign urogenital group (P<0.05)and healthy controls (P<0.05).

There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05).

The HE4 level was also different between patients with a single tumor versus patients with multiple tumors.

CONCLUSIONS: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system.

[MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / blood. Epididymal Secretory Proteins / metabolism. Urologic Neoplasms / blood

Genetic Alliance. consumer health - Transitional cell carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19927341.001).

[ISSN] 1098-2825

[Journal-full-title] Journal of clinical laboratory analysis

[ISO-abbreviation] J. Clin. Lab. Anal.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Specifically, wounds on horse limbs often develop exuberant granulation tissue which behaves clinically like a benign tumor and resembles the human keloid in that the evolving scar is trapped in the proliferative phase of repair, leading to fibrosis.

MedlinePlus Health Information. consumer health - Scars.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 2000 Jan 1;164(1):452-62 [10605042.001]

[Cites] J Surg Res. 2007 Mar;138(1):141-50 [17109886.001]

[Cites] Blood. 2001 Mar 15;97(6):1854-60 [11238129.001]

[Cites] Vet Surg. 2001 May-Jun;30(3):269-77 [11340559.001]

[Cites] J Dermatol Sci. 2001 Nov;27(3):170-7 [11641056.001]

[Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90 [11940533.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]

[Cites] Nature. 2002 Jul 11;418(6894):200-3 [12110892.001]

[Cites] Am J Physiol Cell Physiol. 2002 Sep;283(3):C811-21 [12176738.001]

[Cites] Am J Vet Res. 2002 Nov;63(11):1564-70 [12428668.001]

[Cites] Mol Reprod Dev. 2003 Feb;64(2):152-65 [12506347.001]

[Cites] J Cell Biochem. 2003 Apr 1;88(5):1012-24 [12616538.001]

[Cites] Biochem Biophys Res Commun. 2003 Mar 28;303(1):212-8 [12646189.001]

[Cites] Histochem Cell Biol. 2003 May;119(5):371-81 [12750905.001]

[Cites] Biotechniques. 2003 Jul;35(1):72-8 [12866408.001]

[Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]

[Cites] Diabetes. 2004 Sep;53(9):2509-17 [15331568.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]

[Cites] Science. 1991 Nov 29;254(5036):1359-61 [1962194.001]

[Cites] J Cell Biol. 1992 Sep;118(6):1511-22 [1522121.001]

[Cites] Science. 1993 Dec 3;262(5139):1580-2 [8248808.001]

[Cites] Cell. 1994 Mar 11;76(5):789-91 [7907279.001]

[Cites] J Immunol. 1996 Feb 15;156(4):1515-24 [8568255.001]

[Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]

[Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]

[Cites] J Clin Invest. 1999 Jan;103(1):5-9 [9884328.001]

[Cites] Dev Dyn. 1999 Jan;214(1):44-54 [9915575.001]

[Cites] FEBS Lett. 1999 Jan 15;442(2-3):178-82 [9928997.001]

[Cites] Equine Vet J. 1999 Jan;31(1):61-7 [9952331.001]

[Cites] Development. 1999 May;126(10):2285-98 [10207152.001]

[Cites] J Cell Sci. 1999 Sep;112 Pt 18:3005-14 [10462517.001]

[Cites] Lab Invest. 2005 Mar;85(3):416-25 [15654359.001]

[Cites] N Z Vet J. 2005 Feb;53(1):69-76 [15731837.001]

[Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1225-33 [15766557.001]

[Cites] Am J Pathol. 2005 Jul;167(1):59-69 [15972952.001]

[Cites] Physiol Genomics. 2005 Jul 14;22(2):157-70 [15870397.001]

[Cites] Biol Reprod. 2005 Aug;73(2):324-33 [15829623.001]

[Cites] Wound Repair Regen. 2005 Sep-Oct;13(5):520-9 [16176461.001]

[Cites] BMC Cell Biol. 2006;7:4 [16426441.001]

[Cites] Clin Sci (Lond). 2006 May;110(5):587-95 [16402918.001]

[Cites] Am J Pathol. 2006 Jul;169(1):314-24 [16816383.001]

[Cites] FASEB J. 2001 Feb;15(2):362-72 [11156952.001]

(PMID = 18237399.001).

[ISSN] 1472-6793

[Journal-full-title] BMC physiology

[ISO-abbreviation] BMC Physiol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD31; 0 / beta Catenin

[Other-IDs] NLM/ PMC2268708

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary breast cancer tissues.

ESR1 expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.

[MeSH-minor] Biomarkers, Tumor / genetics. Estrogen Receptor alpha / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Reproducibility of Results

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2000 May 5;275(18):13967-73 [10788523.001]

[Cites] Cancer Lett. 2006 Jun 8;237(1):123-9 [16019133.001]

[Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]

[Cites] Anal Biochem. 2001 Aug 1;295(1):17-21 [11476540.001]

[Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):152-6 [11955624.001]

[Cites] Science. 2002 Apr 19;296(5567):557-9 [11964485.001]

[Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]

[Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]

[Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]

[Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]

[Cites] Biotechniques. 2004 Jan;36(1):84-6, 88, 90-1 [14740490.001]

[Cites] J Pathol. 2004 Apr;202(4):395-402 [15095266.001]

[Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]

[Cites] Genome Biol. 2004;5(8):R59 [15287981.001]

[Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]

[Cites] In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90 [3114226.001]

[Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]

[Cites] Biotechnology (N Y). 1992 Apr;10(4):413-7 [1368485.001]

[Cites] Epithelial Cell Biol. 1992 Jul;1(3):99-104 [1307945.001]

[Cites] Biotechnology (N Y). 1993 Sep;11(9):1026-30 [7764001.001]

[Cites] BMC Cancer. 2006;6:49 [16515701.001]

[Cites] Breast Cancer Res. 2006;8(2):R23 [16626501.001]

[Cites] J Clin Oncol. 2006 Aug 10;24(23):3726-34 [16720680.001]

[Cites] Biotechnol Lett. 2006 Oct;28(19):1601-13 [16900335.001]

[Cites] BMC Cancer. 2006;6:216 [16945123.001]

[Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]

[Cites] Biochem Biophys Res Commun. 1995 Jun 15;211(2):491-6 [7794260.001]

[Cites] Oncol Rep. 1998 Mar-Apr;5(2):469-71 [9468581.001]

[Cites] Nucleic Acids Res. 2004;32(21):6212-7 [15576347.001]

[Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]

[Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]

[Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):69-78 [15688068.001]

[Cites] Clin Cancer Res. 2005 May 1;11(9):3315-9 [15867229.001]

[Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]

[Cites] Anal Biochem. 2005 Jul 1;342(1):69-77 [15958182.001]

[Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):493-8 [16013967.001]

[Cites] Adv Physiol Educ. 2005 Sep;29(3):151-9 [16109794.001]

[Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]

[Cites] Eur Respir J. 2005 Dec;26(6):1002-8 [16319328.001]

[Cites] Clin Cancer Res. 2005 Dec 1;11(23):8348-57 [16322295.001]

[Cites] BMC Bioinformatics. 2006;7:85 [16504059.001]

[Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):95-125 [16460794.001]

[Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]

[Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]

[Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]

(PMID = 18042273.001).

[ISSN] 1471-2199

[Journal-full-title] BMC molecular biology

[ISO-abbreviation] BMC Mol. Biol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human

[Other-IDs] NLM/ PMC2211316

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This retrospective case series evaluates the effectiveness of FOA for the excision of selected benign and malignant rectal tumors.

In the 97 patients evaluated, 99 FOA transanal excisions were performed for 39 adenocarcinomas, 55 benign tumors, and five carcinoid tumors.

The tumors were 0.5 to 13.5 cm in diameter and located an average of 6.9 cm (range, 1 to 15 cm) from the anal verge.

In early follow up of adenomas and favorable T1 carcinomas, FOA transanal excision has similar application, morbidity, and recurrence rates as reported for transanal endoscopic microsurgery for rectal tumors within 15 cm from the anal verge.

[MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / surgery. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / instrumentation. Retrospective Studies

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20726416.001).

[ISSN] 0003-1348

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease.

In 132 cases (27%) it was shown to be a false positive, mainly due to imperfect cleansing of the anal canal; in 284 cases (58%) benign disease was demonstrated (hemorrhoids in 192 patients, abscesses in 21, perianal fistulas in 18, inflamed lymph nodes in 27, polyps in 16).

In 34 patients (7%) a malignant tumor was found (infiltration of the anterior rectal wall by a prostatic adenocarcinoma in 13, and a primitive adenocarcinoma of rectal origin in the remaining 21).

It can be concluded that transrectal US does not permit a certain diagnosis of the nature of rectal disease, but does raise a diagnostic suspicion that can orient the surgeon to schedule more invasive diagnostic investigations.

MedlinePlus Health Information. consumer health - Prostate Diseases.

MedlinePlus Health Information. consumer health - Rectal Disorders.

MedlinePlus Health Information. consumer health - Urine and Urination.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15906788.001).

[ISSN] 1124-3562

[Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

[ISO-abbreviation] Arch Ital Urol Androl

[Language] ENG

[Publication-type] Journal Article

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

It contains the pelvic organs like the inner genital organs of women, the urinary bladder the rectum and parts of the anus.

The rectum is the origin of benign and malign tumors.

Most frequently you find under these tumors the benign adenoma and hamartoma and the malign like the rectal and anal cancer.

The further diagnostic work up and following therapy relates to the histology and the anatomical location of the tumor.

[MeSH-major] Anus Neoplasms. Pelvic Neoplasms. Rectal Neoplasms

[MeSH-minor] Adult. Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Endosonography. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Proctoscopy. Rectum / pathology. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17948756.001).

[ISSN] 0040-5930

[Journal-full-title] Therapeutische Umschau. Revue thérapeutique

[ISO-abbreviation] Ther Umsch

[Language] ger

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Switzerland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nanoscale nuclear architecture for cancer diagnosis beyond pathology via spatial-domain low-coherence quantitative phase microscopy.

Definitive diagnosis of malignancy is often challenging due to limited availability of human cell or tissue samples and morphological similarity with certain benign conditions.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):347-52 [10560513.001]

[Cites] Opt Lett. 2010 Sep 1;35(17):2840-2 [20808342.001]

[Cites] Opt Lett. 2004 Jul 1;29(13):1509-11 [15259729.001]

[Cites] Nat Rev Cancer. 2004 Sep;4(9):677-87 [15343274.001]

[Cites] J Cell Biochem. 1998 Aug 1;70(2):172-80 [9671223.001]

[Cites] Nat Med. 1998 Aug;4(8):882-5 [9701230.001]

[Cites] Nature. 1954 May 1;173(4409):821-2 [13165653.001]

[Cites] Opt Lett. 2005 Aug 15;30(16):2131-3 [16127933.001]

[Cites] Opt Lett. 2005 Sep 15;30(18):2445-7 [16196347.001]

[Cites] Opt Lett. 2006 Mar 15;31(6):775-7 [16544620.001]

[Cites] Opt Lett. 2006 May 15;31(10):1405-7 [16642120.001]

[Cites] Opt Lett. 2006 May 15;31(10):1462-4 [16642139.001]

[Cites] Opt Lett. 2009 Mar 15;34(6):767-9 [19282926.001]

[Cites] Opt Lett. 2009 Nov 1;34(21):3442-4 [19881621.001]

[Cites] Gastroenterology. 2010 Jun;138(6):2127-39 [20420950.001]

[Cites] J Cell Biochem. 1999;Suppl 32-33:183-91 [10629118.001]

(PMID = 21198202.001).

[ISSN] 1560-2281

[Journal-full-title] Journal of biomedical optics

[ISO-abbreviation] J Biomed Opt

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R21 CA152935-01; United States / NCI NIH HHS / CA / R21CA152935; United States / NCI NIH HHS / CA / R21 CA138370; United States / NCI NIH HHS / CA / R21 CA138370-01; United States / NCI NIH HHS / CA / R21 CA152935; United States / NCI NIH HHS / CA / CA138370-02; United States / NCI NIH HHS / CA / R21CA138370; United States / NCI NIH HHS / CA / CA152935-01; United States / NCI NIH HHS / CA / R21 CA138370-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ PMC3025597

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.

A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

Genetic Alliance. consumer health - Meningioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]

[Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]

[Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]

[Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]

[Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]

[Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]

[Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]

[Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]

[Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]

[Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]

[Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]

[Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]

[Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]

[Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]

[Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]

[Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]

[Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]

(PMID = 20196536.001).

[ISSN] 1520-6882

[Journal-full-title] Analytical chemistry

[ISO-abbreviation] Anal. Chem.

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tumour-invasion like wound healing is characterised by the formation of an extracellular matrix with a high tenascin-C content.

Analysis using antibody BC2 indicates that especially the high-molecular tenascin-C (hm tn-C) variants are typically tumour-associated, while distribution in normal tissue is restrictive.

Conventional cytology produced four false-positives when identifying atypical cells in brush biopsies of inflammatory/benign hyperproliferative mucosa (specificity 96%), while 10 in 52 carcinomas and three of eight recurrences were not identified (sensitivity 78%).

[MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis

[MeSH-minor] Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Mouth Mucosa / pathology. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - Biopsy.

MedlinePlus Health Information. consumer health - Oral Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]

[Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]

[Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]

[Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]

[Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]

[Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]

[Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]

[Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]

[Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]

[Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]

[Cites] Oncology. 2003;64(3):245-50 [12697965.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]

[Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]

[Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]

[Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]

[Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]

[Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]

[Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]

[Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]

[Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]

[Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]

[Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]

[Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]

[Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]

[Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]

[Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]

[Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]

[Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]

[Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]

(PMID = 17111122.001).

[ISSN] 1432-6981

[Journal-full-title] Clinical oral investigations

[ISO-abbreviation] Clin Oral Investig

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.

The anal sphincter function after 6 month of the ileoanal anastomosis remained good in 33/39 and acceptable in 6 cases, if the sphincter function was intact praeoperatively.

After the ultra low rectal resections all patients kept the normal anal shpincter function.

[MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17139887.001).

[ISSN] 0354-950X

[Journal-full-title] Acta chirurgica Iugoslavica

[ISO-abbreviation] Acta Chir Iugosl

[Language] eng

[Publication-type] Journal Article

[Publication-country] Serbia and Montenegro

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.

As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.

Both of these benign tumors are known to be at risk of developing into cancer.

During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.

In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.

It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.

[MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood

Genetic Alliance. consumer health - Endometriosis.

MedlinePlus Health Information. consumer health - Endometriosis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17506483.001).

[ISSN] 0887-8013

[Journal-full-title] Journal of clinical laboratory analysis

[ISO-abbreviation] J. Clin. Lab. Anal.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Chromogranin A

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Fibroadenomas are the most common benign breast tumors, occurring mainly in young women.

Their responses to the hormonal environment are similar to those of normal breast tissue, which suggests that steroid receptors may play a role in tumor development.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]

[Cites] Breast J. 1999 Jul;5(4):256-261 [11348297.001]

[Cites] Steroids. 2000 Oct-Nov;65(10-11):571-7 [11108861.001]

[Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]

[Cites] Endocr Relat Cancer. 2003 Jun;10(2):193-202 [12790782.001]

[Cites] Breast. 2003 Oct;12 (5):302-7 [14659144.001]

[Cites] Cancer Res. 1993 Sep 1;53(17):4071-4 [8395336.001]

[Cites] J Biol Chem. 2002 Feb 15;277(7):5209-18 [11717311.001]

[Cites] Steroids. 2003 Nov;68(10-13):771-8 [14667967.001]

[Cites] J Clin Pathol. 2001 Jan;54(1):37-41 [11271786.001]

[Cites] Endocr Rev. 1997 Aug;18(4):502-19 [9267762.001]

[Cites] J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):325-38 [14973394.001]

[Cites] Mol Endocrinol. 1999 Oct;13(10):1657-71 [10517668.001]

[Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]

[Cites] Maturitas. 2004 Sep 24;49(1):16-24 [15351092.001]

[Cites] Endocrine. 2009 Feb;35(1):118-22 [19002614.001]

[Cites] Steroids. 2005 Mar;70(3):153-60 [15763593.001]

[Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]

[Cites] Br J Cancer. 1992 Apr;65(4):601-7 [1562470.001]

[Cites] Cell Mol Life Sci. 2008 Nov;65(23 ):3839-50 [18850315.001]

[Cites] Mol Endocrinol. 2005 Nov;19(11):2713-35 [15976005.001]

[Cites] Epidemiol Rev. 1997;19(2):310-27 [9494790.001]

[Cites] Gynecol Oncol. 2004 May;93(2):394-9 [15099952.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]

[Cites] J Clin Pathol. 2002 May;55(5):371-4 [11986344.001]

[Cites] Breast Cancer Res Treat. 2002 Mar;72(2):163-72 [12038707.001]

[Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]

[Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]

[Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]

[Cites] Curr Probl Diagn Radiol. 2007 Mar-Apr;36(2):66-82 [17331838.001]

[Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]

[Cites] Braz J Med Biol Res. 1996 Dec;29(12):1593-7 [9222417.001]

[Cites] J Mol Endocrinol. 2000 Feb;24(1):33-41 [10656995.001]

[Cites] Cancer Res. 2002 Sep 1;62(17):4849-53 [12208729.001]

[Cites] Mol Endocrinol. 2005 Mar;19(3):574-87 [15563544.001]

[Cites] Jpn J Cancer Res. 2001 Mar;92(3):302-8 [11267940.001]

[Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2963-71 [10443705.001]

[Cites] Endocr Relat Cancer. 2002 Mar;9(1):1-13 [11914179.001]

(PMID = 19367380.001).

[ISSN] 1355-008X

[Journal-full-title] Endocrine

[ISO-abbreviation] Endocrine

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.

METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.

RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.

CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]

[Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]

[Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]

[Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]

[Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]

[Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]

[Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]

[Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]

[Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]

[Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]

[Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]

[Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]

[Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]

[Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]

[Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]

[Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]

[Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]

[Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]

[Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]

[Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]

[Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]

[Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]

[Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]

[Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]

[Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]

[Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]

[Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]

[Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]

[Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]

[Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]

[Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]

[Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]

(PMID = 21278887.001).

[ISSN] 2005-0399

[Journal-full-title] Journal of gynecologic oncology

[ISO-abbreviation] J Gynecol Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC3026304

[Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: To define a threshold value of apparent diffusion coefficient (ADC) with which malignant breast lesions can be distinguished from benign lesions, and to evaluate the ADC change of peri-tumor tissue in breast carcinoma by echo planar-diffusion weighted imaging (EPI-DWI).

The ADC values were compared between malignant and benign lesions.

The ADC values of malignant lesion and layered peri-tumor tissues (from innermost layer 1 to outermost layer 4 with 5 mm every layer) in different directions were compared and the ADC values among different layers were compared.

RESULTS: The ADC value of 35 malignant lesions was statistically lower than that of 22 benign lesions (P < 0.05).

The ADC value of malignant lesions was statistically lower than that of peri-tumor tissues in different directions (P < 0.05).

For peri-tumor tissues, the ADC values increased gradually from layer 1 to layer 4 and there was a significant difference between the ADC values of layer 1 and layer 2 (P < 0.05); while from layer 2 outwards, there was no statistical difference among different layers.

CONCLUSION: ADC value was a sensitive and specific parameter that could help to differentiate benign and malignant breast lesions.

[MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Echo-Planar Imaging / methods

[MeSH-minor] Adult. Aged. Breast / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Hyperplasia. Middle Aged

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1353-8 [16269133.001]

[Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]

[Cites] Breast J. 2006 Jan-Feb;12(1):28-36 [16409584.001]

[Cites] Cir Esp. 2006 Jan;79(1):3-9 [16426527.001]

[Cites] World J Gastroenterol. 2006 Mar 14;12(10):1626-9 [16570359.001]

[Cites] Anal Biochem. 2006 Aug 1;355(1):117-24 [16756932.001]

[Cites] Magn Reson Imaging. 2006 Sep;24(7):843-7 [16916701.001]

[Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]

[Cites] Breast J. 2006 Sep-Oct;12(5 Suppl 2):S174-80 [16958998.001]

[Cites] Gut. 2006 Nov;55(11):1598-605 [16682430.001]

[Cites] Magn Reson Imaging Clin N Am. 2006 Aug;14(3):305-28, v [17098173.001]

[Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]

[Cites] Radiol Med. 2006 Dec;111(8):1124-33 [17171522.001]

[Cites] Histopathology. 2007 Jan;50(2):232-42 [17222252.001]

[Cites] Ai Zheng. 2007 Feb;26(2):168-71 [17298747.001]

[Cites] J Magn Reson Imaging. 2007 Jun;25(6):1101-12 [17520731.001]

[Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):449-54 [17538295.001]

[Cites] J Magn Reson Imaging. 2001 Mar;13(3):335-43 [11241804.001]

[Cites] Radiologe. 2002 Jan;42(1):1-5 [11930535.001]

[Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]

[Cites] Cancer. 2003 Feb 15;97(4):926-33 [12569592.001]

[Cites] Br J Plast Surg. 2003 Jul;56(5):462-70 [12890459.001]

[Cites] Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim [14682107.001]

[Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):39-44 [14732766.001]

[Cites] Cancer. 2004 Jun 1;100(11):2269-80 [15160329.001]

[Cites] Annu Rev Med. 1996;47:285-301 [8712782.001]

[Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]

[Cites] Int J Cancer. 2005 Mar 1;113(6):1022-5 [15515012.001]

[Cites] Rofo. 2005 Jan;177(1):114-8 [15657829.001]

[Cites] Clin Breast Cancer. 2005 Feb;5(6):425-38 [15748463.001]

[Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]

[Cites] Magn Reson Med Sci. 2002 Jul 1;1(2):73-80 [16082129.001]

[Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]

[Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):737-45 [16111473.001]

[Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]

[Cites] Breast Cancer Res Treat. 2005 Dec;94(3):195-8 [16258704.001]

(PMID = 19144163.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ PMC2633008

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Contributions of advanced proteomics technologies to cancer diagnosis.

This discipline incorporates technologies that can be applied to complex biosystems such as serum and tissue in order to characterize the content of, and changes in, the proteome induced by physiological changes, benign or pathologic.

These tools include 2-DE, 2D-DIGE, ICAT, protein arrays, MudPIT and mass spectrometries including SELDI-TOF.

[MeSH-major] Biomarkers, Tumor / analysis. Neoplasms / diagnosis. Neoplasms / genetics. Proteome / analysis. Proteomics / trends

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):59-66 [15797521.001]

[Cites] Mol Cell Proteomics. 2002 Feb;1(2):117-24 [12096129.001]

[Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]

[Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]

[Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]

[Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]

[Cites] J Proteome Res. 2005 Mar-Apr;4(2):377-86 [15822913.001]

[Cites] J Am Soc Mass Spectrom. 2003 Jul;14 (7):760-5 [12837598.001]

[Cites] J Proteome Res. 2004 Mar-Apr;3(2):200-8 [15113095.001]

[Cites] Clin Chem. 2003 Aug;49(8):1272-5 [12881441.001]

[Cites] Int J Oncol. 2006 Jan;28(1):195-200 [16327996.001]

[Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]

[Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]

[Cites] Cancer Res. 2001 Aug 15;61(16):6029-33 [11507047.001]

[Cites] Clin Cancer Res. 2005 Feb 1;11(3):1073-85 [15709174.001]

[Cites] Mol Cell Proteomics. 2004 Apr;3(4):367-78 [14990683.001]

[Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]

[Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]

[Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]

[Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]

[Cites] Cancer Lett. 2005 Aug 26;226(2):101-6 [16039949.001]

[Cites] Brief Funct Genomic Proteomic. 2004 Nov;3(3):220-39 [15642186.001]

[Cites] Blood. 2005 May 1;105(9):3722-30 [15650054.001]

[Cites] Proteomics. 2006 Apr;6(8):2600-8 [16502466.001]

[Cites] Mol Cell Proteomics. 2006 Jan;5(1):157-71 [16215274.001]

[Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]

[Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8 [14523236.001]

[Cites] Methods Mol Biol. 1999;112:531-52 [10027275.001]

[Cites] J Pathol. 2005 May;206(1):39-45 [15772986.001]

[Cites] Clin Cancer Res. 2004 Nov 15;10(22):7500-10 [15569980.001]

[Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]

[Cites] Cancer Sci. 2005 Mar;96(3):197-201 [15771624.001]

[Cites] J Proteome Res. 2004 Mar-Apr;3(2):282-8 [15113105.001]

[Cites] Am J Pathol. 2002 Oct;161(4):1223-33 [12368196.001]

[Cites] Mol Cell Proteomics. 2003 Jul;2(7):443-52 [12824440.001]

[Cites] Proteomics. 2005 May;5(7):1953-66 [15816004.001]

[Cites] Mol Cell Proteomics. 2006 Mar;5(3):433-43 [16319398.001]

[Cites] Lab Invest. 2004 Jul;84(7):845-56 [15107802.001]

[Cites] Methods Mol Biol. 2005;293:255-67 [16028425.001]

[Cites] Biochem Biophys Res Commun. 2003 Sep 12;309(1):18-25 [12943657.001]

[Cites] Mod Pathol. 2004 Jun;17(6):670-8 [15098007.001]

[Cites] J Proteome Res. 2006 May;5(5):1143-54 [16674103.001]

[Cites] BMC Cancer. 2006 Mar 16;6:68 [16542425.001]

[Cites] Prostate Cancer Prostatic Dis. 1999 Dec;2(5/6):264-276 [12497173.001]

[Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]

[Cites] Proteomics. 2003 Mar;3(3):254-64 [12627378.001]

[Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]

[Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]

[Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]

[Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]

[Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]

[Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):98-104 [14732777.001]

[Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]

[Cites] Clin Cancer Res. 2005 Dec 1;11(23):8312-20 [16322290.001]

[Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1197-203 [15865066.001]

[Cites] Clin Chem Lab Med. 2003 Dec;41(12):1562-70 [14708880.001]

[Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]

[Cites] Technol Cancer Res Treat. 2006 Feb;5(1):67-72 [16417404.001]

[Cites] Clin Chim Acta. 2005 Jul 24;357(2):113-22 [15941565.001]

[Cites] Neurol Res. 2006 Mar;28(2):155-63 [16551433.001]

[Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]

[Cites] Protein Expr Purif. 2000 Jun;19(1):12-21 [10833385.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 [14573703.001]

[Cites] Proteomics. 2006 Jan;6(2):697-708 [16252305.001]

[Cites] Cancer Res. 2001 Oct 15;61(20):7585-93 [11606398.001]

[Cites] J Proteome Res. 2004 Mar-Apr;3(2):289-95 [15113106.001]

[Cites] Dis Markers. 2003-2004;19(1):33-9 [14757945.001]

[Cites] Hum Reprod. 2003 May;18(5):915-24 [12721162.001]

[Cites] Clin Cancer Res. 2004 Dec 15;10(24):8380-5 [15623616.001]

[Cites] Oncogene. 2007 Jan 4;26(1):54-64 [16819514.001]

[Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]

[Cites] Hepatology. 2005 Jan;41(1):40-7 [15690480.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):43-52 [14734450.001]

[Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]

[Cites] Nat Methods. 2005 Sep;2(9):691-7 [16118640.001]

[Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]

[Cites] Trends Genet. 2000 Jan;16(1):5-8 [10637622.001]

[Cites] Anal Cell Pathol. 2000;21(1):1-9 [11254220.001]

[Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]

[Cites] Clin Chem. 2005 Apr;51(4):695-707 [15695329.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9390-5 [10920198.001]

[Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]

[Cites] Anal Chem. 2000 Feb 15;72(4):757-63 [10701260.001]

[Cites] J Proteome Res. 2005 Jul-Aug;4(4):1213-22 [16083271.001]

[Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34 [14623978.001]

[Cites] Mol Cell Proteomics. 2005 Apr;4(4):377-83 [15671041.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]

[Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]

[Cites] Nat Rev Cancer. 2004 Aug;4(8):638-44 [15286743.001]

[Cites] FASEB J. 2005 Jul;19(9):1125-7 [15985535.001]

[Cites] Cancer. 2004 May 1;100(9):1814-22 [15112261.001]

[Cites] Int J Oncol. 2004 Jun;24(6):1513-22 [15138595.001]

[Cites] Proteomics. 2003 Dec;3(12):2310-6 [14673781.001]

[Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):860-8 [14871961.001]

[Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):533-7 [9150937.001]

[Cites] Electrophoresis. 2006 Apr;27(8):1641-50 [16550499.001]

[Cites] Clin Chem Lab Med. 2005;43(12):1314-20 [16309366.001]

[Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]

[Cites] Mol Cell Proteomics. 2006 Jun;5(6):1119-30 [16554294.001]

[Cites] Rapid Commun Mass Spectrom. 2004;18(19):2365-6 [15384161.001]

[Cites] Pathol Res Pract. 2005;201(12):763-70 [16308101.001]

[Cites] Biol Mass Spectrom. 1993 Jun;22(6):338-45 [8329463.001]

(PMID = 16952845.001).

[ISSN] 1699-048X

[Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

[ISO-abbreviation] Clin Transl Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome

[Number-of-references] 108

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We describe two types of oligomers formed by the HypF-N protein that are morphologically and tinctorially similar, as detected with atomic force microscopy and thioflavin T assays, though one is benign when added to cell cultures whereas the other is toxic.

[MeSH-minor] Cell Line, Tumor. Cell Membrane / metabolism. Cell Survival. Humans. Hydrophobic and Hydrophilic Interactions. Microscopy, Atomic Force. Protein Binding. Protein Conformation

COS Scholar Universe. author profiles.

BioCyc. gene/protein/disease-specific - hypF .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20081829.001).

[ISSN] 1552-4469

[Journal-full-title] Nature chemical biology

[ISO-abbreviation] Nat. Chem. Biol.

[Language] eng

[Databank-accession-numbers] PDB/ 1GXU

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Escherichia coli Proteins; EC 2.1.3.- / Carboxyl and Carbamoyl Transferases; EC 2.1.3.- / hypF protein, E coli

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cubic membranes thus may offer a new, potentially benign medium for gene transfection.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1995 Aug 11;270(32):18997-9007 [7642560.001]

[Cites] FEBS Lett. 1995 Aug 1;369(1):13-7 [7641875.001]

[Cites] Curr Opin Struct Biol. 1997 Oct;7(5):661-8 [9345624.001]

[Cites] Biosci Rep. 1997 Dec;17(6):507-20 [9561295.001]

[Cites] Chemphyschem. 2004 Oct 18;5(10):1619-23 [15535566.001]

[Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1335-9 [16287225.001]

[Cites] Biochim Biophys Acta. 2005 Dec 30;1746(3):349-63 [16440447.001]

[Cites] J Cell Biol. 2006 Jun 19;173(6):839-44 [16785319.001]

[Cites] J Agric Food Chem. 2007 Mar 7;55(5):1915-22 [17263546.001]

[Cites] Langmuir. 2007 Nov 20;23(24):12003-9 [17949111.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12293-8 [10535915.001]

[Cites] J Struct Biol. 1999 Oct;127(3):231-9 [10544048.001]

[Cites] Nature. 2003 Mar 6;422(6927):37-44 [12621426.001]

[Cites] J Am Chem Soc. 2003 Jun 18;125(24):7188-9 [12797787.001]

[Cites] Mol Ther. 2003 Dec;8(6):957-63 [14664798.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Gene Ther. 1996 Nov;3(11):1010-7 [9044741.001]

(PMID = 18270148.001).

[ISSN] 1742-5689

[Journal-full-title] Journal of the Royal Society, Interface

[ISO-abbreviation] J R Soc Interface

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Phosphorothioate Oligonucleotides; 9007-49-2 / DNA

[Other-IDs] NLM/ PMC2607430

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In human prostate biopsy samples, ABCA1 mRNA expression was ∼2-fold higher in the androgen deprivation therapy group than in subjects with benign prostatic hyperplasia or pretreatment prostate cancer groups.

[MeSH-minor] ATP Binding Cassette Transporter 1. Androgens / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cholesterol / metabolism. Enzyme Activation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Male. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism. Simvastatin / pharmacology

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

Hazardous Substances Data Bank. CHOLESTEROL .

Hazardous Substances Data Bank. SIMVASTATIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 AACR.

[Cites] Curr Opin Lipidol. 2004 Dec;15(6):659-65 [15529025.001]

[Cites] Cancer Res. 2004 Nov 1;64(21):7682-5 [15520169.001]

[Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]

[Cites] Carcinogenesis. 2005 May;26(5):883-91 [15705602.001]

[Cites] Am J Epidemiol. 2005 Aug 15;162(4):318-25 [16014776.001]

[Cites] Trends Cardiovasc Med. 2005 Oct;15(7):265-71 [16226682.001]

[Cites] Biochem Biophys Res Commun. 2006 May 26;344(1):226-32 [16600185.001]

[Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]

[Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]

[Cites] Prostate. 2007 Apr 1;67(5):463-71 [17252538.001]

[Cites] Prostate. 2007 Jul 1;67(10):1061-9 [17469127.001]

[Cites] Clin Chim Acta. 2007 Aug;383(1-2):78-84 [17512923.001]

[Cites] Atherosclerosis. 2008 Jan;196(1):180-9 [17466310.001]

[Cites] J Am Coll Cardiol. 2008 Apr 22;51(16):1604-12 [18420105.001]

[Cites] Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15 [18939908.001]

[Cites] J Urol. 2009 May;181(5):1998-2006; discussion 2007-8 [19286225.001]

[Cites] Endocr J. 2009;56(3):317-34 [18753704.001]

[Cites] Prostate. 2009 Oct 1;69(14):1493-506 [19536794.001]

[Cites] Int J Cancer. 2000 Jan 1;85(1):60-7 [10585584.001]

[Cites] J Urol. 2000 Mar;163(3):1027-32 [10688043.001]

[Cites] Carcinogenesis. 2001 May;22(5):701-7 [11323387.001]

[Cites] J Lipid Res. 2001 Jun;42(6):967-75 [11369805.001]

[Cites] J Biol Chem. 2001 Aug 24;276(34):31780-5 [11427538.001]

[Cites] Circulation. 2001 Oct 16;104(16):1978-83 [11602504.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Int J Cancer. 2002 Jun 20;99(6):846-52 [12115487.001]

[Cites] Mol Cell Biol. 2002 Aug;22(16):5962-74 [12138205.001]

[Cites] Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7 [12207878.001]

[Cites] J Biol Chem. 2003 Mar 14;278(11):9142-9 [12511559.001]

[Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]

[Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):712-9 [12615688.001]

[Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):802-8 [12637339.001]

[Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]

[Cites] Cancer Res. 2004 Feb 15;64(4):1515-21 [14973113.001]

[Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):790-4 [15033469.001]

[Cites] Cancer. 1973 Jul;32(1):196-205 [4123791.001]

[Cites] Anal Biochem. 1975 May 12;65(1-2):42-9 [165752.001]

[Cites] Methods Enzymol. 1986;129:628-44 [3523160.001]

[Cites] Cancer. 1989 Aug 1;64(3):598-604 [2743254.001]

[Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9 [8105097.001]

[Cites] Science. 1996 Jan 26;271(5248):518-20 [8560269.001]

[Cites] J Urol. 2005 Feb;173(2):342-59 [15643172.001]

(PMID = 20671065.001).

[ISSN] 1557-3125

[Journal-full-title] Molecular cancer research : MCR

[ISO-abbreviation] Mol. Cancer Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / / NIH0013975756; United States / PHS HHS / / NIH0013975756; United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / ABCA1 protein, human; 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Lipoproteins, HDL; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 97C5T2UQ7J / Cholesterol; AGG2FN16EV / Simvastatin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

[Other-IDs] NLM/ NIHMS222887; NLM/ PMC2941551

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa.

Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.

Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.

MedlinePlus Health Information. consumer health - Bone Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]

[Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]

[Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]

[Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]

[Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]

[Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]

[Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]

[Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]

[Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]

[Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]

[Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]

[Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]

[Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]

[Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]

[Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]

[Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]

[Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]

[Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]

[Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]

[Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]

[Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]

[Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]

[Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]

[Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]

[Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]

[Cites] Surg Today. 1994;24(5):476-80 [8054822.001]

[Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]

[Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]

[Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]

[Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]

(PMID = 19838726.001).

[ISSN] 1432-2307

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We report here on a preliminary investigation of ganglioside composition and structure in human hemangioma, a benign tumor in the frontal cortex (HFC) in comparison to normal frontal cortex (NFC) tissue using for the first time advanced mass spectrometric methods based on fully automated chip-nanoelectrospray (nanoESI) high-capacity ion trap (HCT) and collision-induced dissociation (CID).

Fragmentation analysis by CID in MS(2) mode using as precursors the ions corresponding to GT1 (d18:1/20:0) and GD1 (d18:1/20:0) provided data corroborating for the first time the presence of the common GT1a and GT1b isomers and the incidence of unusual GT1c and GT1d glycoforms in brain hemangioma tumor.

[MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gangliosides / chemistry. Gangliosides / metabolism. Hemangioma / metabolism. Spectrometry, Mass, Electrospray Ionization / methods. Tandem Mass Spectrometry / methods

Genetic Alliance. consumer health - Hemangioma.

MedlinePlus Health Information. consumer health - Birthmarks.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19841910.001).

[ISSN] 1618-2650

[Journal-full-title] Analytical and bioanalytical chemistry

[ISO-abbreviation] Anal Bioanal Chem

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gangliosides; GZP2782OP0 / N-Acetylneuraminic Acid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months.

Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n=140, P-value <0.0001).

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]

[Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]

[Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]

[Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]

[Cites] Carcinogenesis. 2007 Dec;28(12):2467-75 [17690110.001]

[Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):1-10 [10696454.001]

[Cites] Int J Cancer. 2000 May 20;89(3):230-5 [10861498.001]

[Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]

[Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]

[Cites] J Cell Physiol. 2001 Feb;186(2):153-68 [11169452.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]

[Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]

[Cites] J Cell Biochem. 2002;86(4):665-77 [12210733.001]

[Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]

[Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]

[Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]

[Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]

[Cites] Cancer. 2004 Sep 15;101(6):1345-56 [15316903.001]

[Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]

[Cites] J Urol. 1982 Oct;128(4):858-61 [7143620.001]

[Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]

[Cites] Nature. 1984 Jan 12-18;307(5947):131-6 [6318122.001]

[Cites] Endocrinology. 1990 Mar;126(3):1343-54 [2307108.001]

[Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):722-30 [2384450.001]

[Cites] Cell. 1991 Jan 25;64(2):231 [1846319.001]

[Cites] Acta Anat (Basel). 1992;143(2):139-50 [1598820.001]

[Cites] J Cell Sci. 1992 Jun;102 ( Pt 2):361-72 [1400638.001]

[Cites] Cancer. 1994 Aug 1;74(3 Suppl):1030-44 [8039137.001]

[Cites] Carcinogenesis. 1995 Jul;16(7):1499-503 [7614683.001]

[Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]

[Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]

[Cites] J Histochem Cytochem. 1998 Mar;46(3):379-88 [9487120.001]

[Cites] Cancer Res. 1998 Jun 15;58(12):2520-3 [9635571.001]

[Cites] Clin Cancer Res. 1998 Jul;4(7):1625-30 [9676836.001]

[Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]

[Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]

[Cites] Clin Cancer Res. 1996 Aug;2(8):1255-61 [9816295.001]

[Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]

[Cites] Genes Cells. 1998 Oct;3(10):659-70 [9893023.001]

[Cites] Mol Cancer. 2007;6:69 [17967179.001]

[Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]

[Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]

[Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]

[Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]

[Cites] Oncogene. 2006 May 4;25(19):2773-84 [16407846.001]

[Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]

[Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]

[Cites] Rev Endocr Metab Disord. 2006 Jun;7(1-2):41-9 [16944325.001]

[Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]

[Cites] Growth Factors. 1998;16(2):101-10 [9932228.001]

[Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]

[Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]

[Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]

(PMID = 18724388.001).

[ISSN] 1476-5594

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA108646; United States / NIGMS NIH HHS / GM / F31 GM079879; United States / PHS HHS / / FGM079879A; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / R01 CA108646-04; United States / NCI NIH HHS / CA / T32 CA009592; United States / NCI NIH HHS / CA / R01 CA108646; None / None / / R01 CA108646-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Ligands; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor

[Other-IDs] NLM/ NIHMS142310; NLM/ PMC3222150

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.

Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.

Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.

However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.

These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYCLOPAMINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]

[Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]

[Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]

[Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]

[Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]

[Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]

[Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]

[Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]

[Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]

[Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]

[Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]

[Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]

[Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]

[Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]

[Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]

[Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]

[Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]

[Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]

[Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]

[Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]

[Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]

[Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]

[Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]

[Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]

[Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]

[Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]

[Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]

[Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]

[Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]

[Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]

[Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]

[Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]

[Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]

[Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]

[Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]

[Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]

[Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]

[Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]

[Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]

[Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]

[Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]

[Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]

[Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]

[Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]

[Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]

(PMID = 16855373.001).

[ISSN] 1538-4047

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine

[Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.

Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.

Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.

Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.

Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways.

Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.

These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

MedlinePlus Health Information. consumer health - Pituitary Tumors.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.

[Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]

[Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]

[Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]

[Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]

[Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]

[Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]

[Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]

[Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]

[Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]

[Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]

[Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]

[Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]

[Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]

[Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]

[Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]

[Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]

[Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]

[Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]

[Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]

[Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]

[Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]

[Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]

[Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]

[Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]

[Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]

[Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]

[Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]

[Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]

[Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]

[Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]

[Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]

[Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]

[Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]

[Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]

[Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]

[Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]

[Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]

[Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]

[Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]

[Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]

[Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]

[Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]

[Cites] Pituitary. 2009;12(1):40-50 [18270844.001]

[Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]

[Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]

[Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]

[Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]

[Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]

[Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]

[Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]

[Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]

(PMID = 20153804.001).

[ISSN] 1872-8057

[Journal-full-title] Molecular and cellular endocrinology

[ISO-abbreviation] Mol. Cell. Endocrinol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1

[Publication-type] Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human

[Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Papillomavirus is a pathogenic virus that induces benign tumor at the infected lesion, and its association with malignant tumor was first identified by R.

Because of its clinical importance, the study on HPV has been focused on the oncogenic properties, and the results of which had great impacts on the researches of the tumor suppressors, such as p53 and pRb, and "ubiquiitn-proteasome" pathway.

[MeSH-minor] Animals. Gene Expression Regulation, Viral. Gene Silencing. Genes, Tumor Suppressor. Genome, Viral. Humans. Open Reading Frames / genetics. Virus Replication / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19374194.001).

[ISSN] 0042-6857

[Journal-full-title] Uirusu

[ISO-abbreviation] Uirusu

[Language] jpn

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Japan

[Number-of-references] 33

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation.

There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05).

The resection of tumor can decrease the proportion of Treg in peripheral blood.

[MeSH-major] Antigens, CD / immunology. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / immunology. T-Lymphocytes, Regulatory / immunology. Urologic Neoplasms / immunology

Genetic Alliance. consumer health - Transitional cell carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19623656.001).

[ISSN] 1098-2825

[Journal-full-title] Journal of clinical laboratory analysis

[ISO-abbreviation] J. Clin. Lab. Anal.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-7 Receptor alpha Subunit

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A long-echo-time rotor-synchronized Carr-Purcell-Meiboom-Gill (CPMG) sequence including an electronic reference to access in vivo concentrations (ERETIC) standard was used to determine the concentrations of lactate and alanine in 82 benign and 16 malignant biopsies (mean 26.5% +/- 17.2% of core).

Low concentrations of lactate (0.61 +/- 0.28 mmol/kg) and alanine (0.14 +/- 0.06 mmol/kg) were observed in benign prostate biopsies, and there was no significant difference between benign predominantly glandular (N = 54) and stromal (N = 28) biopsies between patients with (N = 38) and without (N = 44) a positive clinical biopsy.

In biopsies containing prostate cancer there was a highly significant (P < 0.0001) increase in lactate (1.59 +/- 0.61 mmol/kg) and alanine (0.26 +/- 0.07 mmol/kg), and minimal overlap with lactate concentrations in benign biopsies.

This study demonstrates for the first time very low concentrations of lactate and alanine in benign prostate biopsy tissues.

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. (L)-ALANINE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Urology. 2006 Aug;68(2):244-8 [16904427.001]

[Cites] Endocr Relat Cancer. 2006 Sep;13(3):739-49 [16954428.001]

[Cites] Cancer Res. 2006 Nov 15;66(22):10855-60 [17108122.001]

[Cites] Radiology. 2007 Apr;243(1):28-53 [17392247.001]

[Cites] Abdom Imaging. 2007 Mar-Apr;32(2):253-61 [17476554.001]

[Cites] Magn Reson Med. 2007 Jul;58(1):65-9 [17659629.001]

[Cites] Magn Reson Med. 2007 Dec;58(6):1099-106 [17969006.001]

[Cites] Lung Cancer. 2006 Oct;54(1):95-102 [16890323.001]

[Cites] Radiology. 1999 Nov;213(2):473-80 [10551229.001]

[Cites] J Radiol. 2004 Dec;85(12 Pt 1):1999-2004 [15692410.001]

[Cites] Radiology. 2005 Mar;234(3):804-14 [15734935.001]

[Cites] Clin Exp Metastasis. 2005;22(1):25-30 [16132575.001]

[Cites] Solid State Nucl Magn Reson. 2006 Feb;29(1-3):214-8 [16229992.001]

[Cites] Radiology. 2006 Feb;238(2):597-603 [16344335.001]

[Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):523-30 [16471314.001]

[Cites] Mol Cell Biochem. 2005 Dec;280(1-2):1-8 [16511951.001]

[Cites] Curr Opin Oncol. 2006 May;18(3):284-8 [16552242.001]

[Cites] J Invest Dermatol. 2006 Jun;126(6):1378-87 [16543892.001]

[Cites] Magn Reson Med. 2006 Jun;55(6):1257-64 [16685733.001]

[Cites] Radiology. 1999 Nov;213(2):481-8 [10551230.001]

[Cites] Radiol Clin North Am. 2000 Jan;38(1):115-38, viii-ix [10664669.001]

[Cites] J Urol. 2000 Aug;164(2):400-4 [10893595.001]

[Cites] FEBS Lett. 2001 Apr 6;494(1-2):112-6 [11297745.001]

[Cites] Magn Reson Med. 2001 Jul;46(1):49-57 [11443710.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53 [11567808.001]

[Cites] Radiology. 2001 Nov;221(2):380-90 [11687679.001]

[Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):321-6 [12827509.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63 [12930897.001]

[Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]

[Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4223-7 [14666629.001]

[Cites] Magn Reson Med. 2004 Jul;52(1):147-53 [15236378.001]

[Cites] Curr Med Chem. 2004 Aug;11(16):2195-204 [15279558.001]

[Cites] J Biol Chem. 1984 May 25;259(10):6215-21 [6144677.001]

[Cites] Magn Reson Med. 1991 Jun;19(2):429-38 [1715505.001]

[Cites] Magn Reson Med. 1993 Mar;29(3):285-91 [7680746.001]

[Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]

[Cites] Prostate. 1994 Sep;25(3):162-6 [7520580.001]

[Cites] Cancer Res. 1995 Nov 1;55(21):4757-9 [7585499.001]

[Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]

[Cites] Gynecol Oncol. 1997 Sep;66(3):399-404 [9299252.001]

[Cites] NMR Biomed. 1997 Dec;10(8):411-22 [9542738.001]

[Cites] J Magn Reson. 1998 Aug;133(2):243-54 [9716465.001]

[Cites] Radiology. 2004 Nov;233(2):441-8 [15375223.001]

[Cites] Magn Reson Med. 2005 Jan;53(1):41-8 [15690501.001]

(PMID = 18727052.001).

[ISSN] 1522-2594

[Journal-full-title] Magnetic resonance in medicine

[ISO-abbreviation] Magn Reson Med

[Language] ENG

[Grant] United States / NIBIB NIH HHS / EB / R21 EB005363-03; United States / NCI NIH HHS / CA / K01 CA96618; United States / NCI NIH HHS / CA / K01 CA096618-04; United States / NCI NIH HHS / CA / R01 CA102751; United States / NIBIB NIH HHS / EB / R21 EB05363; United States / NCI NIH HHS / CA / CA096618-04; United States / NIBIB NIH HHS / EB / EB005363-03; United States / NIBIB NIH HHS / EB / R21 EB005363; United States / NCI NIH HHS / CA / K01 CA096618

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Lactates; OF5P57N2ZX / Alanine

[Other-IDs] NLM/ NIHMS83785; NLM/ PMC2613807

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.

OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.

The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.

RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%).

In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases.

CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management.

In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.

MedlinePlus Health Information. consumer health - Pericardial Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20701070.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The histologic examination revealed the presence of a discontinuous rim of compressed thyroid follicles on the outer aspect of the tumor capsule.

The patient was free of disease after 22 months, in accordance with the benign behavior of immature teratoma in infancy.

Genetic Alliance. consumer health - Teratoma.

Hazardous Substances Data Bank. THYROGLOBULIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19736871.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

Biospecimen Research Database. Biospecimen Research Database .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]

[Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]

[Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]

[Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]

[Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]

[Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]

[Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]

[Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]

[Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]

[Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]

[Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]

[Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]

[Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]

[Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]

[Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]

[Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]

[Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]

[Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]

[Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]

[Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]

[Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]

[Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]

[Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]

[Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]

[Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]

[Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]

[Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]

[Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]

[CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]

[CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]

(PMID = 17981926.001).

[ISSN] 0009-9147

[Journal-full-title] Clinical chemistry

[ISO-abbreviation] Clin. Chem.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530